Mer­ck scores an­oth­er win for King Keytru­da, this time in HER2-neg­a­tive can­cer

Mer­ck’s an­ti-PD1 on­col­o­gy megablock­buster Keytru­da is plan­ning on adding an­oth­er in­di­ca­tion to its ar­ray, tout­ing a Phase III win in its march to reg­u­la­tors.

Mer­ck put out word Tues­day that one of its Phase III tri­als, KEYNOTE-859, nailed the pri­ma­ry end­point of over­all sur­vival in pa­tients with a spe­cif­ic type of HER2-neg­a­tive ade­no­car­ci­no­ma. Keytru­da com­bined with chemother­a­py beat out chemo at a pre-de­ter­mined in­ter­im analy­sis. Mer­ck added that sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ments in PFS and ORR were al­so ob­served.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER